STSP-0601 for Injection

DRUG5 trials

Sponsors

Staidson (Beijing) Biopharmaceuticals Co., Ltd, Jiangsu BioJeTay Biotechnology Co., Ltd.

Conditions

Hemophilia

Phase 1

A Safety Study of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor

CompletedNCT04747964

Staidson (Beijing) Biopharmaceuticals Co., LtdHemophilia

Start: 2020-01-15End: 2021-04-19Updated: 2024-09-19

A Safety and Efficacy Study of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor

CompletedNCT05027230

Staidson (Beijing) Biopharmaceuticals Co., LtdHemophilia

Start: 2021-10-12End: 2023-07-29Updated: 2024-09-19

Phase 2

Safety and Efficacy of STSP-0601 in Adult Patients With Hemophilia A or B Without Inhibitor

CompletedNCT05619926

Staidson (Beijing) Biopharmaceuticals Co., LtdHemophilia

Start: 2023-01-09End: 2023-08-25Updated: 2024-01-02

Safety and Efficacy of STSP-0601 in Adult Patients with Hemophilia a or B with Inhibitor

CompletedNCT06289166

Staidson (Beijing) Biopharmaceuticals Co., LtdHemophilia

Start: 2024-03-18End: 2024-10-17Updated: 2025-01-22

Phase 3

Phase III Clinical Trial of STSP-0601 for Injection in Hemophilia Patients

Active, not recruitingNCT06922045

Jiangsu BioJeTay Biotechnology Co., Ltd.Hemophilia

Start: 2025-03-26End: 2027-03-01Updated: 2026-08-12

Related Papers

A specific FX activator for bleeding treatment in hemophilia with inhibitors: multicenter, open-label, phase I/II trials

Blood Advances2026-02-04

A Specific Coagulation Factor X Activator for on-Demand Treatment in Hemophilia with Inhibitors

Blood2024-11-05